62 results
Page 2 of 4
8-K
EX-99.1
8utafuv
15 May 23
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
7:00am
8-K
jf7to63m5ylvm i84w3
5 Dec 22
Other Events
6:47am
8-K
EX-99.1
bdsd38dh sb28poh6ord
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
8-K
EX-99.1
l5h7plan
9 Aug 22
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
6:45am
8-K
EX-1.1
talwoj qj
21 Jul 22
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4:46pm
8-K
iaytdopu44rb5
21 Jul 22
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4:46pm
8-K
EX-99.1
7s2tf9py6u qh9
21 Jul 22
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
4:46pm
8-K
axa0vu7p6dj3ocsx3
12 Jul 22
Other Events
7:00am
S-3
EX-1.2
z0r gv0w0
1 Jul 22
Shelf registration
4:36pm
8-K
EX-99.1
ejjr5jtshia8
10 May 22
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
6:48am
10-K
7mt6dt1izhh4fxylf
14 Mar 22
Annual report
7:04am
10-K
EX-10.14
bpd f3oc4i
14 Mar 22
Annual report
7:04am
8-K
EX-99.1
23xgzh9q2 ee
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am